Related Experiment Videos
Targeting C5a: recent advances in drug discovery
M Allegretti1, A Moriconi, A R Beccari
1Dompé Research and Development, Dompé s.p.a., L'Aquila, Italy. marcello.allegretti@dompe.it
Current Medicinal Chemistry
|January 11, 2005
Summary
Complement activation, particularly C5a, drives diseases like ARDS and RA. Inhibiting C5a offers therapeutic potential for inflammatory disorders without compromising immune defense.
Area of Science:
- Immunology
- Pharmacology
- Drug Discovery
Background:
- Complement system activation is crucial for host defense but implicated in diseases like psoriasis, ARDS, RA, and I/R injury.
- The C5a peptide, a potent chemoattractant released during complement activation, plays a key role in inflammation.
- Unregulated complement activation contributes to the pathogenesis of various inflammatory and autoimmune conditions.
Purpose of the Study:
- To review recent advancements in C5a inhibition strategies.
- To highlight the potential of targeting C5a for managing complement-mediated diseases.
- To emphasize the value of a multidisciplinary approach in C5a-targeted drug discovery.
Main Methods:
- Review of pharmacological studies on C5a antagonists.
- Analysis of recombinant proteins and humanized anti-C5 antibodies for complement inhibition.
- Examination of mutagenesis data for the C5a/C5a receptor (C5aR) complex.
Main Results:
- C5a is identified as a key therapeutic target for complement-mediated diseases.
- Development of peptide and non-peptide C5a antagonists, including orally active compounds.
- C5aR serves as a valuable model for studying peptidergic G-protein coupled receptors (GPCRs).
Conclusions:
- Specific inhibition of C5a activity may offer therapeutic benefits in inflammatory disorders.
- Targeting C5a can potentially treat diseases without impairing essential immune responses.
- Integrated, multidisciplinary drug discovery approaches are vital for advancing C5a-based therapeutics.